Tempest Therapeutics(TPST) - 2023 Q4 - Annual Results

Exhibit 99.1 Tempest Reports Year End 2023 Financial Results and Provides Business Update Brisbane, CA, March 19, 2024 – Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the year ended 2023 and provided a corporate update. "2023 was a transformative year for Tempest. We announced strong positive randomized data showing the benefit of TPST-1120 combinatio ...